Author

Daniela Villalobos

Pontificia Universidad Católica de Chile

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander NguyeniD· 1 shared Azime Akçaöz-AlasariD· 1 shared Benjamin Lozano· 1 shared Bünyamin AkgüliD· 1 shared Carlos Andrés Ramírez Parrado· 1 shared Claudio R. AlarcóniD· 1 shared Cristian VargasiD· 1 shared Denis Ostapenko· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alexander NguyenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

METTL3 promotes cell cycle progression via activation of transcriptional elongation.

Azime Akçaöz-Alasar, Yanhua Wang, Hang Li, Denis Ostapenko, Carlos Andrés Ramírez Parrado, Daniela Villalobos, Hengyi Li, Prajwal Chaitanya Boddu, Alexander Nguyen, Marcelo Pérez-Pepe, Pénélope Darnat, Bünyamin Akgül, Manoj M. Pillai, Yansheng Liu, Lilian Kabeche, Claudio R. Alarcón

The paper shows that METTL3 phosphorylation by CDK1 promotes transcriptional elongation and cell cycle progression through the m6A/7SK/P-TEFb axis.

Molecular Cell · Jul 31, 2026Peer-reviewedMolecular Biology

Tocilizumab induces significant changes in longitudinal proteomes of blood serum from patients with severe COVID-19 pneumonia

José Cordero, Graciela Bravo, Pedro H. Silva, Benjamin Lozano, Elizabeth Rivas, Valeria Labra, Daniela Villalobos, Pablo Saldivia, Mauricio Hernández, Elard S. Koch, Cristian Vargas, Estefanía Nova-Lamperti, Nelson P. Barrera, Jaime Retamal

This study shows that tocilizumab reduces inflammation in severe COVID-19 by altering serum proteomes, restoring protein levels to healthy states.

bioRxiv · May 6, 2026 · PreprintPharmacology & Toxicology